Aldevron News / Aldevron

Aldevron capacity, capability growth key to gene, cell and protein therapeutics research

0319-GEN-logoAldevron is "Driven by a Passion to Enable Science," as featured in the April Genetic Engineering & Biotechnology News. This article spans our new production facility in Fargo, North Dakota, and the expansion of our Freiburg, Germany, antibody facility, to our expanding CRISPR options, the publication discusses our ongoing push to help researchers in their work.

One particular highlight is the discussion of our new CRISPR options, including GMP level SpyFiTM Cas9 Nuclease and the availability of in-stock GMP level prepacked CRISPR nucleases.

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies

Austin, Texas, Cambridge, Mass. and Fargo, N.D. – September 26, 2018 – Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.

Read More